Equities Analysts Issue Forecasts for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Wedbush lifted their FY2024 earnings per share (EPS) estimates for shares of Compass Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.32) per share for the year, up from their previous forecast of ($0.39). Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.28) EPS, FY2026 earnings at $0.31 EPS and FY2028 earnings at $1.76 EPS.

A number of other brokerages have also weighed in on CMPX. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Monday.

Compass Therapeutics Stock Performance

CMPX opened at $1.59 on Friday. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.34. The firm has a 50-day moving average price of $1.76 and a two-hundred day moving average price of $1.42.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC acquired a new position in shares of Compass Therapeutics during the 1st quarter worth about $80,000. Renaissance Technologies LLC boosted its position in shares of Compass Therapeutics by 99.7% during the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock worth $141,000 after purchasing an additional 70,200 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after purchasing an additional 12,315 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Compass Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock valued at $8,221,000 after buying an additional 71,008 shares during the period. Finally, Panagora Asset Management Inc. acquired a new stake in Compass Therapeutics during the 2nd quarter worth $68,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.